Q2-osavuosiraportti
27 päivää sitten‧42 min
6,00 NOK/osake
Viimeisin osinko
2,45 %
Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
10
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 27 | - | - | ||
| 81 | - | - | ||
| 1 | - | - | ||
| 66 | - | - | ||
| 48 | - | - |
Ylin
247VWAP
Alin
242VaihtoMäärä
1 4 131
VWAP
Ylin
247Alin
242VaihtoMäärä
1 4 131
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 24.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 8.5. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 24.10.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
3.9.·Little activity here, anyone have any thoughts? Everyone has had a solid first half of the year💪4.9.·I think they can increase prices a bit without losing much, since they have a strong niche position. But in the long run, growth will probably come mostly from volume and new markets.
21.8.·Medistim Danske Bank Buy Buy 310 260 Simon Larsson 2 1 0
24.8.·Harryjh, what stocks do you have? You've never been afraid to share.
20.8.·EBIT in H2 this year is about 70% above the level after H1 2021, while the share is still about 30% lower. Medistim is under-analyzed and "forgotten", and should be priced as a growth company again after today's guidance and results. The ATH of NOK 400 from September 2021 should now be within reach, if not for too long. Enjoy being on the journey, and congratulations to everyone on the rise today!21.8. · Muokattu·I myself have given 148kr. It is absolutely true that Medistim is a forgotten jewel. Ergo why we have poor liquidity in the box. Personally, I think that we are approaching a bit of rigid pricing in the share, but I have to look at the numbers for q2. Generally speaking, you can expect just under 20% growth in EPS with Medistim. The last 10 years at least. So we will see if this growth indicates a multiple increase or not. But again, I never sell just because the share is expensive. Quality can cost, and it can cost a long time. One thing is certain when it comes to the health sector. It is far safer and better to be an investor in the part that supplies equipment, rather than those that supply and develop medicines.
20.8.20.8.Read my full analysis of Medistim below. A heart surgeon’s best friend. https://nordicedge.substack.com/p/medistim-medi-a-heart-surgeons-best
20.8.·Koloka, this was an excellent analysis on Medstim! You are talking about stenting. Stenting is used as a solution before going to bypass with Medistim's method CABG as the final permanent solution. Recapitulate what emerged during Capital Markets Day last year with a surgeon(?) Puskas who stated that we have already seen "peak stenting". Because this method is on the decline because stenting with inflating clogged arteries can cause plaque that is the cause of clogged arteries to come loose in the blood system and can result in infarction on all fronts. Again good analysis Koloka!20.8.20.8.Thank you for the kind words. My substack is dedicated to uncover quality opportunities in the Nordics - it is completely free to subscribe :-) re. Puskas' comment about "peak stenting" at the CMD, I think he may be right from a theoretical standpoint - e.g., doctors are stenting too much. But the facts are that doctors continue to stent more, hence, I don't think we have "seen the top" of stening. At least, that is what all my interviews and public data suggest. That said, it is not binary. CABG and stenting can (and should) co-exist. New CABG technologies (i.e. minimally invasive CABG) may gain traction but it is still far too early to say for certain. Similarly, new technologies within stenting may pull in the other direction. However, as surrounding technologies (e.g. for diagnosis) improve, and an "objective" measurement of when a patient should be stented vs. CABG, then I think CABG will grow as a share. The "issue" right now is that the doctors who diagnose the patient (subjectively) can do the stenting right away, whereas they would have to refer the patient to a surgeon for CAGB procedure. In other words, they gatekeep CAGB volumes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
27 päivää sitten‧42 min
6,00 NOK/osake
Viimeisin osinko
2,45 %
Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3.9.·Little activity here, anyone have any thoughts? Everyone has had a solid first half of the year💪4.9.·I think they can increase prices a bit without losing much, since they have a strong niche position. But in the long run, growth will probably come mostly from volume and new markets.
- 21.8.·Medistim Danske Bank Buy Buy 310 260 Simon Larsson 2 1 024.8.·Harryjh, what stocks do you have? You've never been afraid to share.
- 20.8.·EBIT in H2 this year is about 70% above the level after H1 2021, while the share is still about 30% lower. Medistim is under-analyzed and "forgotten", and should be priced as a growth company again after today's guidance and results. The ATH of NOK 400 from September 2021 should now be within reach, if not for too long. Enjoy being on the journey, and congratulations to everyone on the rise today!21.8. · Muokattu·I myself have given 148kr. It is absolutely true that Medistim is a forgotten jewel. Ergo why we have poor liquidity in the box. Personally, I think that we are approaching a bit of rigid pricing in the share, but I have to look at the numbers for q2. Generally speaking, you can expect just under 20% growth in EPS with Medistim. The last 10 years at least. So we will see if this growth indicates a multiple increase or not. But again, I never sell just because the share is expensive. Quality can cost, and it can cost a long time. One thing is certain when it comes to the health sector. It is far safer and better to be an investor in the part that supplies equipment, rather than those that supply and develop medicines.
- 20.8.20.8.Read my full analysis of Medistim below. A heart surgeon’s best friend. https://nordicedge.substack.com/p/medistim-medi-a-heart-surgeons-best20.8.·Koloka, this was an excellent analysis on Medstim! You are talking about stenting. Stenting is used as a solution before going to bypass with Medistim's method CABG as the final permanent solution. Recapitulate what emerged during Capital Markets Day last year with a surgeon(?) Puskas who stated that we have already seen "peak stenting". Because this method is on the decline because stenting with inflating clogged arteries can cause plaque that is the cause of clogged arteries to come loose in the blood system and can result in infarction on all fronts. Again good analysis Koloka!20.8.20.8.Thank you for the kind words. My substack is dedicated to uncover quality opportunities in the Nordics - it is completely free to subscribe :-) re. Puskas' comment about "peak stenting" at the CMD, I think he may be right from a theoretical standpoint - e.g., doctors are stenting too much. But the facts are that doctors continue to stent more, hence, I don't think we have "seen the top" of stening. At least, that is what all my interviews and public data suggest. That said, it is not binary. CABG and stenting can (and should) co-exist. New CABG technologies (i.e. minimally invasive CABG) may gain traction but it is still far too early to say for certain. Similarly, new technologies within stenting may pull in the other direction. However, as surrounding technologies (e.g. for diagnosis) improve, and an "objective" measurement of when a patient should be stented vs. CABG, then I think CABG will grow as a share. The "issue" right now is that the doctors who diagnose the patient (subjectively) can do the stenting right away, whereas they would have to refer the patient to a surgeon for CAGB procedure. In other words, they gatekeep CAGB volumes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
10
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 27 | - | - | ||
| 81 | - | - | ||
| 1 | - | - | ||
| 66 | - | - | ||
| 48 | - | - |
Ylin
247VWAP
Alin
242VaihtoMäärä
1 4 131
VWAP
Ylin
247Alin
242VaihtoMäärä
1 4 131
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 24.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 8.5. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 24.10.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
27 päivää sitten‧42 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 24.10. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 20.8. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2024 Yhtiökokous | 8.5. | |
| 2024 Q4-osavuosiraportti | 28.2. | |
| 2024 Q3-osavuosiraportti | 24.10.2024 |
Datan lähde: Millistream, Quartr
6,00 NOK/osake
Viimeisin osinko
2,45 %
Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 3.9.·Little activity here, anyone have any thoughts? Everyone has had a solid first half of the year💪4.9.·I think they can increase prices a bit without losing much, since they have a strong niche position. But in the long run, growth will probably come mostly from volume and new markets.
- 21.8.·Medistim Danske Bank Buy Buy 310 260 Simon Larsson 2 1 024.8.·Harryjh, what stocks do you have? You've never been afraid to share.
- 20.8.·EBIT in H2 this year is about 70% above the level after H1 2021, while the share is still about 30% lower. Medistim is under-analyzed and "forgotten", and should be priced as a growth company again after today's guidance and results. The ATH of NOK 400 from September 2021 should now be within reach, if not for too long. Enjoy being on the journey, and congratulations to everyone on the rise today!21.8. · Muokattu·I myself have given 148kr. It is absolutely true that Medistim is a forgotten jewel. Ergo why we have poor liquidity in the box. Personally, I think that we are approaching a bit of rigid pricing in the share, but I have to look at the numbers for q2. Generally speaking, you can expect just under 20% growth in EPS with Medistim. The last 10 years at least. So we will see if this growth indicates a multiple increase or not. But again, I never sell just because the share is expensive. Quality can cost, and it can cost a long time. One thing is certain when it comes to the health sector. It is far safer and better to be an investor in the part that supplies equipment, rather than those that supply and develop medicines.
- 20.8.20.8.Read my full analysis of Medistim below. A heart surgeon’s best friend. https://nordicedge.substack.com/p/medistim-medi-a-heart-surgeons-best20.8.·Koloka, this was an excellent analysis on Medstim! You are talking about stenting. Stenting is used as a solution before going to bypass with Medistim's method CABG as the final permanent solution. Recapitulate what emerged during Capital Markets Day last year with a surgeon(?) Puskas who stated that we have already seen "peak stenting". Because this method is on the decline because stenting with inflating clogged arteries can cause plaque that is the cause of clogged arteries to come loose in the blood system and can result in infarction on all fronts. Again good analysis Koloka!20.8.20.8.Thank you for the kind words. My substack is dedicated to uncover quality opportunities in the Nordics - it is completely free to subscribe :-) re. Puskas' comment about "peak stenting" at the CMD, I think he may be right from a theoretical standpoint - e.g., doctors are stenting too much. But the facts are that doctors continue to stent more, hence, I don't think we have "seen the top" of stening. At least, that is what all my interviews and public data suggest. That said, it is not binary. CABG and stenting can (and should) co-exist. New CABG technologies (i.e. minimally invasive CABG) may gain traction but it is still far too early to say for certain. Similarly, new technologies within stenting may pull in the other direction. However, as surrounding technologies (e.g. for diagnosis) improve, and an "objective" measurement of when a patient should be stented vs. CABG, then I think CABG will grow as a share. The "issue" right now is that the doctors who diagnose the patient (subjectively) can do the stenting right away, whereas they would have to refer the patient to a surgeon for CAGB procedure. In other words, they gatekeep CAGB volumes.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
10
Myynti
Määrä
200
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 27 | - | - | ||
| 81 | - | - | ||
| 1 | - | - | ||
| 66 | - | - | ||
| 48 | - | - |
Ylin
247VWAP
Alin
242VaihtoMäärä
1 4 131
VWAP
Ylin
247Alin
242VaihtoMäärä
1 4 131
Välittäjätilasto
Dataa ei löytynyt